Tandem Diabetes Care (TNDM) Stock
Insulin pump designer for automated diabetes care. Here's the price, business snapshot, and what's worth knowing about Tandem Diabetes Care in May 2026.
Tandem Diabetes Care, Inc. (TNDM) designs and manufactures insulin delivery systems for people with type 1 and advanced type 2 diabetes. Its flagship product, the t:slim X2 insulin pump integrates with continuous glucose monitors and software features such as the Control‑IQ automated insulin delivery algorithm and over‑the‑air updates. The company earns revenue from pump sales, consumable supplies and software-related services and competes on ease of use, interoperability and regulatory approvals. At a market capitalisation of about $1.04 billion, Tandem is a small-cap medical devices company exposed to the growing diabetes care market. Investors should watch device adoption, regulatory milestones, reimbursement trends and partnerships. Key risks include competition from larger device makers, reimbursement uncertainty, supply-chain constraints and the potential for rapid technology change. This is general educational information and not personalised investment advice; consider your own circumstances or speak to a qualified adviser about suitability and risk.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Tandem Diabetes Care's stock, expecting its value to rise significantly.
Financial Health
Tandem Diabetes Care shows strong revenue and cash flow, with healthy profit margins supporting growth.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring TNDM
At-Home Treatment Revolution | FDA Approval Impact
The FDA's approval of an injectable, at-home version of Eisai and Biogen's Alzheimer's drug signals a major shift in chronic disease management. This creates an investment opportunity in companies that develop advanced drug delivery systems and support at-home patient care.
Published: September 1, 2025
Explore BasketPharma's Digital Prescription
Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.
Published: August 19, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Device Adoption Trends
Investors may watch increasing pump and CGM adoption as a demand driver, though uptake can vary by region and payer policies.
Software Differentiation
Control‑IQ and over‑the‑air updates can extend product value, but software and regulatory issues may affect performance and approvals.
Market & Reimbursement
Rising diabetes prevalence supports long-term demand; however, reimbursement changes and competition can influence revenue and margins.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
